drugset / Trial / NCT05065866
Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy
Phase 1
Completed
14 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Secura Bio, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug BMS-986345, in combination with duvelisib.
Timeline
- Start
- 2021-11-18
- Primary completion
- 2024-01-02
- Completion
- 2024-04-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 100 mg | — |
| Subject | Azacitidine | Other / unclassified | 200 mg | — |
| Subject | Azacitidine | Other / unclassified | 300 mg | — |
| Subject | Duvelisib | Small molecule | 15 mg | — |
| Subject | Duvelisib | Small molecule | 25 mg | — |
| Subject | Duvelisib | Small molecule | 50 mg | — |
| Subject | Duvelisib | Small molecule | 75 mg | — |